These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25454794)

  • 1. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
    Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
    J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
    McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
    Cirillo D; Pentimalli F; Giordano A
    Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
    Premnath PN; Craig SN; Liu S; McInnes C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
    Chen P; Lee NV; Hu W; Xu M; Ferre RA; Lam H; Bergqvist S; Solowiej J; Diehl W; He YA; Yu X; Nagata A; VanArsdale T; Murray BW
    Mol Cancer Ther; 2016 Oct; 15(10):2273-2281. PubMed ID: 27496135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
    Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
    ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
    Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
    Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity and potency of cyclin-dependent kinase inhibitors.
    Sridhar J; Akula N; Pattabiraman N
    AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural dissection of cyclin dependent kinases regulation and protein recognition properties.
    Lolli G
    Cell Cycle; 2010 Apr; 9(8):1551-61. PubMed ID: 20372077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
    Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
    Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.